Sex-Specific Differences in Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty

Paweł Kurzyna1,2, Anna Witowicz3, Piotr Kędzierski1

  • 1Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, European Health Center Otwock, Centre of Postgraduate Medical Education, ERN-LUNG Member, 05-400 Otwock, Poland.

PubMed

Insights

Women with chronic thromboembolic pulmonary hypertension (CTEPH) present with worse baseline hemodynamics but show superior response to balloon pulmonary angioplasty (BPA) compared to men. This suggests potential sex-specific differences in CTEPH management.

Area of Science:

  • Cardiovascular Medicine
  • Pulmonary Hypertension Research
  • Interventional Cardiology

Background:

  • Sex-specific differences in cardiovascular diseases are recognized, yet under-researched in chronic thromboembolic pulmonary hypertension (CTEPH).
  • Limited data exists on sex-based outcomes following balloon pulmonary angioplasty (BPA) for CTEPH.

Purpose of the Study:

  • To investigate and compare sex-specific differences in CTEPH patients undergoing BPA treatment.
  • To evaluate hemodynamic and clinical outcomes between men and women post-BPA.

Main Methods:

  • Retrospective analysis of 94 CTEPH patients treated with BPA.
  • Assessment of hemodynamic and clinical parameters at baseline and 3 months post-BPA.

Main Results:

  • Women exhibited higher baseline systolic pulmonary arterial pressure (sPAP) and pulmonary vascular resistance than men.
  • Post-BPA, women showed improved sPAP, pulmonary capillary wedge pressure, and cardiac index.
  • Women achieved a greater reduction in mean pulmonary artery pressure and better Dyspnea Borg Scale scores.

Conclusions:

  • Women with CTEPH present with more severe baseline hemodynamic compromise but experience better outcomes after BPA.
  • Women appear to have better disease adaptation and response to BPA compared to men.
  • Further research is warranted to determine if sex-differentiated management strategies are beneficial for CTEPH patients.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
147